Overview

This trial is active, not recruiting.

Condition meningococcal infections
Treatments 4cmenb, diphtheria,tetanus,pertussis+polio+hepatitis b+hib, conjugated pneumococcal vaccine, mmrv
Sponsor Centre Hospitalier Universitaire de Québec, CHU de Québec
Collaborator GlaxoSmithKline
Start date August 2008
End date August 2010
Trial size 4535 participants
Trial identifier NCT02712177, 1224

Summary

Bexsero™ is a four component serogroup B meningococcal vaccine (4CMenB) licensed in Europe, Canada, and Australia in 2014. Prelicensure studies and post marketing surveillance data showed that 4CMenB has a high reactogenicity especially when coadministered with other infant routine vaccines [1-2]. While this suggests that coadministration causes an interaction resulting in a greater risk of adverse events following Immunization (AEFI) only the AEFI after the 4CMenB dose and not those occurring after routine vaccine immunizations were reported, underestimating the total risk associated with immunization at separate visits. For financial and practical reasons, coadministration of infant vaccines is preferred to separate visits. Separate visits may however be preferred if the sum of the AEFI risk at each visit is significantly smaller than the risk with coadministration and/or if the AEFI has a lesser severity. The purpose of this study is to recalculate the risk of occurrence and severity of AEFI with the coadministration of Bexsero™ and routine vaccines compared to separate injections to assess the interaction occurring with co-administration. Investigators will also estimate the risk of recurrence of AEFI at subsequent immunizations with the 4CMenB and assess if this risk varies with separate or coadministration with routine vaccines. To achieve these purposes, investigators will perform a secondary analysis of the data of three randomized controlled trials (clinicaltrials.gov identifiers: NCT00657709, NCT00847145 and NCT00721396) that evaluated 5025 children aged 2 to 14 months of whom 4535 were randomized to receive 3 to 4 doses of 4CMenB concomitantly or alternatively with routine vaccinations (DTaP-IPV-HepB/Hib [Infanrix Hexa™], PCV7 [Prevenar™] or MMRV [Priorix-Tetra™]) [1,2].

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective retrospective
Arm
Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).
4cmenb Bexsero
diphtheria,tetanus,pertussis+polio+hepatitis b+hib Infanrix Hexa
conjugated pneumococcal vaccine Prevenar
Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..
4cmenb Bexsero
diphtheria,tetanus,pertussis+polio+hepatitis b+hib Infanrix Hexa
conjugated pneumococcal vaccine Prevenar
Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.
4cmenb Bexsero
diphtheria,tetanus,pertussis+polio+hepatitis b+hib Infanrix Hexa
conjugated pneumococcal vaccine Prevenar
mmrv Priorix Tetra
Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.
4cmenb Bexsero
diphtheria,tetanus,pertussis+polio+hepatitis b+hib Infanrix Hexa
conjugated pneumococcal vaccine Prevenar
Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.
4cmenb Bexsero
diphtheria,tetanus,pertussis+polio+hepatitis b+hib Infanrix Hexa
conjugated pneumococcal vaccine Prevenar
mmrv Priorix Tetra
Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.
diphtheria,tetanus,pertussis+polio+hepatitis b+hib Infanrix Hexa
conjugated pneumococcal vaccine Prevenar
Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.
diphtheria,tetanus,pertussis+polio+hepatitis b+hib Infanrix Hexa
conjugated pneumococcal vaccine Prevenar

Primary Outcomes

Measure
Fever
time frame: AT RISK INTERVAL 4CMenB and inactivated routine vaccines (InRV) : Onset 24 hours following immunization (post-Imm). MMRV: Onset day 5 to day 13 post-Imm.CONTROL INTERVAL 4CMenB and InRV : Onset day 4 to 7post-Imm . MMRV: Onset day 0 to 4 post-Imm
Systemic reactions other than fever
time frame: AT RISK INTERVAL 4CMenB and InRV : Onset 24 hours post-Imm. MMRV: Onset day 5 to day 13 post-Imm.CONTROL INTERVAL 4CMenB and InRV : Onset day 4 to 7post-Imm . MMRV: Onset day 0 to 4 post-Imm
Fever or systemic reactions other than fever
time frame: AT RISK INTERVAL 4CMenB and InRV : Onset 24 hours post-Imm. MMRV: Onset day 5 to day 13 post-Imm.CONTROL INTERVAL 4CMenB and InRV : Onset day 4 to 7post-Imm . MMRV: Onset day 0 to 4 post-Imm
Injection site reactions
time frame: AT RISK INTERVAL all injection site reactions regardless of their delay of onset. Baseline (CONTROL) risk null.

Eligibility Criteria

Male or female participants from 2 months up to 14 months old.

Inclusion Criteria: - Healthy 2-month old infants (55-89 days, inclusive), who were born after full term pregnancy with an estimated gestational age ≥ 37 weeks - Parent/legal guardian has given written informed consent after the nature of the study has been explained. Main exclusion Criteria : - History of any meningococcal B or C vaccine administration; prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens); - Previous ascertained or suspected disease caused by N. meningitidis; History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component; - Significant acute or chronic infection within the previous 7 days or axillary temperature major or equal to38 degrees within the previous day; - Antibiotics within 6 days prior to enrollment; - Any serious chronic or progressive disease; - Known or suspected impairment or alteration of the immune system; - Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.

Additional Information

Official title Interaction Between Meningococcal Serogroup B Vaccine (Bexsero™) and Routine Infant Vaccines on the Risk of Occurrence and Recurrence of Adverse Events Following Immunization.
Principal investigator Gaston De Serres, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Centre Hospitalier Universitaire de Québec, CHU de Québec.